CPA Applauds FDA Proposal to Strengthen U.S. Generic Drug Manufacturing and Supply Chain Integrity

CPA Applauds FDA Proposal to Strengthen U.S. Generic Drug Manufacturing and Supply Chain Integrity

CPA welcomes new proposals from the Food and Drug Administration (FDA) aimed at rebuilding domestic generic drug manufacturing, strengthening oversight of foreign pharmaceutical production, and improving supply chain transparency.

New CPA Report Shows Domestic Manufacturing Market Share Rebounds in 2025 as Tariffs Begin to Reshape U.S. Industry

New CPA Report Shows Domestic Manufacturing Market Share Rebounds in 2025 as Tariffs Begin to Reshape U.S. Industry

The report finds that the CPA Domestic Market Share Index (DMSI) – which measures the share of U.S. demand served by domestic producers – rebounded in 2025 as Section 232 tariffs and other industrial policies began to reshape the competitive landscape for American industry.

CPA Applauds Suniva’s Major U.S. Solar Cell Manufacturing Investment

CPA Applauds Suniva’s Major U.S. Solar Cell Manufacturing Investment

Suniva’s expansion highlights the critical importance of rebuilding the domestic crystalline silicon photovoltaic (PV) supply chain—particularly solar cell manufacturing, one of the most strategically important segments of U.S. energy production.

New Fed Research Backs CPA's Case on China's Industrial Policy and Record Surplus

New Fed Research Backs CPA’s Case on China’s Industrial Policy and Record Surplus

A new Federal Reserve FEDS Note finds a systematic link between Chinese industrial policy interventions and export growth. The 15 most policy-targeted sectors accounted for 76% of the increase in China’s aggregate trade surplus from 2017 to 2024.